Login to Your Account



Prothena, Roche target alpha-synuclein in $600M Parkinson’s pact

By Cormac Sheridan
Staff Writer

Wednesday, December 11, 2013

DUBLIN – Shares in Prothena Corp. plc should get a pre-Christmas boost when Nasdaq opens on Thursday morning to news of a drug development deal in Parkinson’s disease with Roche Holding AG worth up to $600 million in up-front and milestone payments.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription